OÜ CeleCure

Active Registry code 10872161 OÜ Tallinn Registered 5 Jun 2002
Compare

OÜ CeleCure is a OÜ based in Tallinn, registry code 10872161, status: active. Main activity: Research and experimental development on biotechnology. Its annual report for 2025 shows revenue of €0 and 0 employees.

Turnover
—
State taxes
—
Labour taxes
—
Employees
1
±0 vs Q2 2026

Q3 2026 · data from the Tax and Customs Board (EMTA)

Position in the industry Scientific research and development · EMTAK 72

  • Revenue · 2025 0 €
    industry median 0 € · companies in the industry: 1 073

Taxes and turnover

Q4 2023 – Q3 2026
Employees Q3 2026: 1 · +0.0% vs Q2 2026
0.00.20.40.60.81.0Q4 2023 Company: 1Q4·23Q1 2024 Company: 1Q2 2024 Company: 1Q2·24Q3 2024 Company: 1Q4 2024 Company: 1Q4·24Q1 2025 Company: 1Q2 2025 Company: 1Q2·25Q3 2025 Company: 1Q4 2025 Company: 1Q4·25Q1 2026 Company: 1Q2 2026 Company: 1Q2·26Q3 2026 Company: 1Q3·260.00.20.40.60.81.0Q4 2024 Company: 1Q1 2025 Company: 1Q1·25Q2 2025 Company: 1Q3 2025 Company: 1Q3·25Q4 2025 Company: 1Q1 2026 Company: 1Q1·26Q2 2026 Company: 1Q3 2026 Company: 1Q3·26
Figures by quarter
Quarter Turnover, € State taxes, € Labour taxes, € Employees
Q3 2026 — — — 1
Q2 2026 — — — 1
Q1 2026 — — — 1
Q4 2025 — — — 1
Q3 2025 — — — 1
Q2 2025 — — — 1
Q1 2025 — — — 1
Q4 2024 — — — 1
Q3 2024 — — — 1
Q2 2024 — — — 1
Q1 2024 — — — 1
Q4 2023 — — — 1
Q3 2023 — — — 1
Q2 2023 — — — 1
Q1 2023 — — — 1
Q4 2022 — — — 1
Q3 2022 — — — 1
Q2 2022 — — — 1
Q1 2022 — — — 1

Financials by year

2016 – 2025
Revenue, € 2025: 0 € · industry median 0 € · above 5% of the industry
0501001502016 Company: — Industry median: —20162017 Company: — Industry median: —20172018 Company: — Industry median: —20182019 Company: 0 € Industry median: 0 €20192020 Company: 0 € Industry median: 150 €20202021 Company: 0 € Industry median: 0 €20212022 Company: 0 € Industry median: 103 €20222023 Company: 0 € Industry median: 76 €20232024 Company: 0 € Industry median: 0 €20242025 Company: 0 € Industry median: 0 €20250501001502018 Company: — Industry median: —2019 Company: 0 € Industry median: 0 €20192020 Company: 0 € Industry median: 150 €2021 Company: 0 € Industry median: 0 €20212022 Company: 0 € Industry median: 103 €2023 Company: 0 € Industry median: 76 €20232024 Company: 0 € Industry median: 0 €2025 Company: 0 € Industry median: 0 €2025
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit, € 2025: -200 € · industry median 0 € · above 29% of the industry
-200-150-100-500502016 Company: — Industry median: —20162017 Company: — Industry median: —20172018 Company: — Industry median: —20182019 Company: 0 € Industry median: 3 €20192020 Company: 0 € Industry median: 28 €20202021 Company: 0 € Industry median: 1 €20212022 Company: 0 € Industry median: 0 €20222023 Company: 0 € Industry median: 0 €20232024 Company: 0 € Industry median: 0 €20242025 Company: -200 € Industry median: 0 €2025-200-150-100-500502018 Company: — Industry median: —2019 Company: 0 € Industry median: 3 €20192020 Company: 0 € Industry median: 28 €2021 Company: 0 € Industry median: 1 €20212022 Company: 0 € Industry median: 0 €2023 Company: 0 € Industry median: 0 €20232024 Company: 0 € Industry median: 0 €2025 Company: -200 € Industry median: 0 €2025
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Assets, € 2025: 2 572 € · −7.2% vs 2024
01 0002 0003 0002016 Company: —20162017 Company: —20172018 Company: —20182019 Company: 2 772 €20192020 Company: 2 772 €20202021 Company: 2 772 €20212022 Company: 2 772 €20222023 Company: 2 772 €20232024 Company: 2 772 €20242025 Company: 2 572 €202501 0002 0003 0002018 Company: —2019 Company: 2 772 €20192020 Company: 2 772 €2021 Company: 2 772 €20212022 Company: 2 772 €2023 Company: 2 772 €20232024 Company: 2 772 €2025 Company: 2 572 €2025
Equity, € 2025: 2 529 € · −7.3% vs 2024
01 0002 0003 0002016 Company: —20162017 Company: —20172018 Company: —20182019 Company: 2 729 €20192020 Company: 2 729 €20202021 Company: 2 729 €20212022 Company: 2 729 €20222023 Company: 2 729 €20232024 Company: 2 729 €20242025 Company: 2 529 €202501 0002 0003 0002018 Company: —2019 Company: 2 729 €20192020 Company: 2 729 €2021 Company: 2 729 €20212022 Company: 2 729 €2023 Company: 2 729 €20232024 Company: 2 729 €2025 Company: 2 529 €2025
Employees 2025: 0 · industry median 1 · above 2% of the industry
0.00.51.01.52.02016 Company: 0 Industry median: —20162017 Company: 0 Industry median: —20172018 Company: 0 Industry median: 120182019 Company: 0 Industry median: 120192020 Company: 0 Industry median: 120202021 Company: 0 Industry median: 120212022 Company: 0 Industry median: 220222023 Company: 0 Industry median: 120232024 Company: 0 Industry median: 120242025 Company: 0 Industry median: 120250.00.51.01.52.02018 Company: 0 Industry median: 12019 Company: 0 Industry median: 120192020 Company: 0 Industry median: 12021 Company: 0 Industry median: 120212022 Company: 0 Industry median: 22023 Company: 0 Industry median: 120232024 Company: 0 Industry median: 12025 Company: 0 Industry median: 12025
  • Company
  • Industry median

Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Financials by year
Year Revenue, € Net profit, € Labour costs, € Assets, € Equity, € Employees
2025 0 -200 0 2 572 2 529 0
2024 0 0 0 2 772 2 729 0
2023 0 0 0 2 772 2 729 0
2022 0 0 0 2 772 2 729 0
2021 0 0 0 2 772 2 729 0
2020 0 0 0 2 772 2 729 0
2019 0 0 0 2 772 2 729 0
2018 — — — — — 0
2017 — — — — — 0
2016 — — — — — 0
2015 — — — — — 1
2014 — — — — — 1
2013 — — — — — 1
2012 — — — — — 1
2011 — — — — — 1
2010 — — — — — 6
2009 — — — — — 9
2008 — — — — — 20
2007 — — — — — 9
2006 — — — — — 6
2005 — — — — — 11
2004 — — — — — 11
2003 — — — — — 4

Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.

Financial ratios for 2025

Return on equity (ROE)
-7.9 %
Net profit / equity
Return on assets (ROA)
-7.8 %
Net profit / assets
Equity ratio
98.3 %
Equity / assets
Debt ratio
1.7 %
Liabilities / assets
Current ratio
59.81
Current assets / current liabilities

Annual reports

PDFs from e-Äriregister
Annual reports
Year Period Filed Report Documents
2025 1 Jan 2025 – 31 Dec 2025 2 Jul 2026 Company’s own e-Äriregister
2024 1 Jan 2024 – 31 Dec 2024 6 Oct 2025 Company’s own e-Äriregister
2023 1 Jan 2023 – 31 Dec 2023 6 Nov 2024 Company’s own e-Äriregister
2022 1 Jan 2022 – 31 Dec 2022 19 Feb 2024 Company’s own e-Äriregister
2021 1 Jan 2021 – 31 Dec 2021 14 Feb 2024 Company’s own e-Äriregister
2020 1 Jan 2020 – 31 Dec 2020 15 Apr 2021 Company’s own e-Äriregister
2019 1 Jan 2019 – 31 Dec 2019 15 Apr 2021 Company’s own e-Äriregister

Commercial pledges

No. Amount Pledgee Period
1 3 000 000 EEK IBCC Holding AS 27 Oct 2005 – in force

Board

  • Andres Valkna
    Board member · since 8 May 2007
  • Nasdaq CSD SE
    Keeper of the share register · since 28 Sep 2017

Right of representation

Any member of the management board may represent the private limited company in all transactions.

Owners

Beneficial owners

Founders and other persons

shared board members, owners or beneficial owners

Activities (EMTAK)

  • 72111Research and experimental development on biotechnology Main
Rulings
Number, date Title Deadline State Document
Ä 10065741 / M14
6 Oct 2025
Fine for not filing the report 21 Oct 2025 Deficiencies eliminated
16 Oct 2025
PDF
Ä 10065741 / M13
1 Sep 2025
Warning of a fine: annual report not filed 1 Oct 2025 In force
1 Sep 2025
PDF
Ä 10065741 / M12
9 Oct 2024
Warning of a fine: annual report not filed 11 Dec 2024 Deficiencies eliminated
6 Nov 2024
PDF
Ä 10065741 / M11
5 Feb 2024
Warning of a fine: annual report not filed 6 Mar 2024 Deficiencies eliminated
19 Feb 2024
PDF
Ä 10065741 / M10
15 Apr 2021
Warning of a fine: annual report not filed 15 May 2021 Deficiencies eliminated
15 Apr 2021
PDF
Ä 10065741 / 13
17 Jan 2018
Amendment entry In force
17 Jan 2018
PDF
Ä 10065741 / 12
8 Nov 2017
Amendment entry In force
8 Nov 2017
PDF
Ä 10065741 / 11
28 Sep 2017
Amendment entry In force
28 Sep 2017
PDF
Ä 10065741 / 10
2 Sep 2016
Amendment entry In force
2 Sep 2016
PDF
Ä 10065741 / 9
5 Oct 2015
Amendment entry In force
5 Oct 2015
PDF
Ä 10065741 / M9
30 Sep 2015
Ruling to eliminate deficiencies 10 Oct 2015 Deficiencies eliminated
5 Oct 2015
PDF
Ä 10065741 / 8
20 Apr 2015
Amendment entry In force
20 Apr 2015
PDF
Ä 10065741 / M8
9 Apr 2015
Ruling to eliminate deficiencies 19 Apr 2015 Deficiencies eliminated
20 Apr 2015
PDF
Ä 10065741 / M7
30 Mar 2015
Ruling to eliminate deficiencies 29 Apr 2015 Deficiencies eliminated
20 Apr 2015
PDF
Ä 10065741 / 7
16 Mar 2015
Transformation entry In force
16 Mar 2015
PDF
Ä 65741 / M6
16 Oct 2009
Fine for not filing the report 20 Nov 2009 In force
5 Nov 2009
PDF
Ä 65741 / 6
5 Jan 2009
Deletion of activities from the registry card In force
6 Jan 2009
PDF
Ä 65741 / M5
5 Jun 2008
Warning of deletion from the register: annual report not filed Deficiencies eliminated
16 Oct 2008
PDF
Ä 65741 / 5
21 Nov 2007
Amendment entry In force
21 Nov 2007
PDF
Ä 65741 / M4
31 Oct 2007
Fine for not filing the report In force
9 Nov 2007
PDF
Ä 65741 / M3
28 May 2007
Refund of the state fee In force
28 May 2007
PDF
Ä 65741 / M2
16 May 2007
Refund of the state fee In force
16 May 2007
PDF
Ä 65741 / 4
8 May 2007
Amendment entry In force
8 May 2007
PDF
Ä 65741 / 3
15 Nov 2006
Amendment entry In force
15 Nov 2006
PDF
Ä 65741 / M1
12 Jun 2006
Warning of deletion from the register: annual report not filed Deficiencies eliminated
2 Oct 2006
PDF
K 92931
27 Oct 2005
Commercial pledge entered In force PDF
Ä 65741 / 2
7 Apr 2004
Amendment entry In force PDF
Ä 65741
5 Jun 2002
First entry In force PDF

Sources: e-Äriregister and EMTA. Data updated 1 Nov 2026. Open at the source ↗ · Report an error in the data